Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
112 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor - Pipeline Review, H2 2016, provides an overview of the Peripheral Nerve Sheath Tumor (Oncology) pipeline landscape. Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Peripheral Nerve Sheath Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Peripheral Nerve Sheath Tumor. Peripheral Nerve Sheath Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Oncology). - The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Overview 6 Therapeutics Development 7 Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview 7 Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis 8 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Development by Companies 9 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Investigation by Universities/Institutes 10 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Development by Companies 13 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Investigation by Universities/Institutes 14 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development 15 Bexion Pharmaceuticals LLC 15 EpiZyme Inc 16 Merck & Co Inc 17 Novartis AG 18 Pfizer Inc 19 Plexxikon Inc 20 Vyriad Inc 21 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 axitinib - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BXQ-350 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 everolimus - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 ganetespib - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Oncolytic Virus to Target CD46 for Oncology - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 pembrolizumab - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 pexidartinib - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 tazemetostat - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects 109 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones 110 Featured News & Press Releases 110 Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer 110 Appendix 111 Methodology 111 Coverage 111 Secondary Research 111 Primary Research 111 Expert Panel Validation 111 Contact Us 111 Disclaimer 112
List of Tables
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2016 7 Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 15 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by EpiZyme Inc, H2 2016 16 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, H2 2016 17 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, H2 2016 18 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, H2 2016 19 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, H2 2016 20 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, H2 2016 109
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.